JMP Securities analyst Constantine Davides maintained a Hold rating on Progyny (PGNY - Research Report) today. The company's shares closed yesterday at $17.18.

According to TipRanks, Davides is an analyst with an average return of -32.3% and a 25.33% success rate. Davides covers the Healthcare sector, focusing on stocks such as AMN Healthcare Services, Option Care Health, and Evolent Health.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Progyny with a $23.71 average price target.

The company has a one-year high of $42.08 and a one-year low of $13.93. Currently, Progyny has an average volume of 2.17M.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Progyny, Inc. is a medical device company, which engages in the field of reproductive medicine, translating scientific discoveries related to early embryo development into clinical tools. Its services include egg freezing, IVF treatment, surrogacy, podcast, adoption, and Eeva Test. The company was founded on April 03, 2008 and is headquartered in New York, NY.